A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB IN COMBINATION WITH VEMURAFENIB AND/OR COBIMETINIB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2016
Price : $35 *
At a glance
- Drugs Cobimetinib (Primary) ; Onartuzumab (Primary) ; Vemurafenib (Primary)
- Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Roche
- 01 Aug 2016 Status changed from completed to withdrawn prior to enrolment.
- 05 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jul 2014 Planned End Date changed from 1 Sep 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.